Slide 1: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery 3Q25 Financial Results November 5, 2025
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schröding
Slide 3: Recent Updates
Recent Updates 3Q25 Financial Results Portfolio • $54.3M total revenue (+54%) • Plan to complete SGR-1505 and SGR-3515 dose • $40.9M software revenue (+28%) escalation studies • $13.5M drug discovery revenue • Exploring strategic opportunities for SGR-1505 clinical development Updated 2025 Financial
Slide 4: Digital Chemistry Laboratory Leverages Physics + AI
Digital Chemistry Laboratory Leverages Physics + AI Physics + AI/ML Physics-based Training Set for AI/ML Artificial Intelligence / Methods Generated Using Physics Machine Learning ✓ No training set required ✓ Fast ✓ Effective at interpolation ✓ Can extrapolate into novel ✓ Accurate ✓ Fast chemical s
Slide 5: Multi-Pronged Business Enabled by Highly Differentiated Computational Platform
Multi-Pronged Business Enabled by Highly Differentiated Computational Platform SOFTWARE LICENSING • Life Sciences COLLABORATIONS • Materials Design • Drug Design INTERNAL PORTFOLIO ~1,752 customers worldwide1 • Materials Design 19 drug discovery collaborators2 • Drug Discovery & Development 7+ activ
Slide 6: Platform Validated by Clinical Success
Platform Validated by Clinical Success(1)(2) Phase 1 Phase 2 Phase 3 FDA-Approved TIBSOVO4 Immuno-oncology Metabolic Diseases3 Psoriasis3 IDHIFA4 Myelofibrosis Inflammatory Bowel Disease5 Hematologic Malignancies Obesity Solid Tumors Additional programs in discovery and preclinical development with:
Slide 7: Advancing the Platform in 2025
Advancing the Platform in 2025 Continuing to Integrate Physics & AI/ML Target Hit Lead Preclinical Validation Discovery Optimization Development High Resolution Protein Biologics Informatics Formulation & Crystal Structure Prediction Structure Prediction AI/ML Integration in Informatics Platform Vir
Slide 8: Clinical Programs with Breakthrough Potential
Clinical Programs with Breakthrough Potential SGR-1505 SGR-3515 (MALT1) (Wee1/Myt1) • Phase 1 ongoing in patients • Phase 1 ongoing in patients with advanced R/R B-cell with advanced solid tumors malignancies • Initial data expected 1H 2026 • Encouraging initial Phase 1 data presented in June 2025 8
Slide 9: 3Q25 Financial Highlights vs. 3Q24
3Q25 Financial Highlights vs. 3Q24 Three Months Ended September 30 3Q 2024 3Q 2025 % Change Software revenue $31.9 $40.9 28% Drug discovery revenue $3.4 $13.5 295% Total revenue $35.3 $54.3 54% Gross profit $17.7 $28.0 Software gross margin 73% 73% Operating expenses $86.2 $74.0 (14%) Other income $
Slide 10: Four-Quarter Trailing Average Software Quarterly Revenue Trend
Four-Quarter Trailing Average Software Quarterly Revenue Trend 52.5 50.2 50 48.9 45.1 42.3 39.8 40.1 41.6 40 33.9 33.7 33.5 34.6 30.0 31.5 31.6 30 28.3 $ Millions 24.6 24.9 23.1 23.8 21.3 19.6 20 18.0 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2020 2020 2020 2021
Slide 11: 2025 Financial Guidance
2025 Financial Guidance (As of November 5, 2025) 2024 Actual 2025 Guidance Software revenue $180.4M +8% – 13% Drug discovery revenue $27.2M $49M – $52M Software gross margin 80% 73% – 75% Operating expenses $341.4M Lower than 2024 Significantly lower Cash used in operating activities $157.4M than 20
Slide 12: Strategic Priorities
Strategic Priorities • Complete Phase 1 dose escalation studies for SGR-1505 and SGR-3515 • Present initial Phase 1 clinical data for SGR-3515 in 1H26 • Increase customer adoption of computational platform • Deliver planned major enhancements to the platform • Advance therapeutics portfolio for part
Slide 13: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery November 2025
Slide 14: Appendix
Appendix Annual Contract Value (ACV). With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period. For contracts with a duration of more than one